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Abstract. 
The incidence of double primary malignancy in colorectal cancer is rare (approximately 
1-6%), and synchronous double primary malignancy is even rarer for cases involving colorectal 
cancer. Indeed, its incidence is estimated to be less than 1%. The probability of concurrent col-
orectal cancer and lung cancer, in particular, is extremely low (approximately 0.1%). In this re-
port, we present such a case of synchronous primary lung cancer and pulmonary metastatic 
colorectal cancer, which was mistaken for primary lung cancer with lung-to-lung metastasis. 
Tumors were identified in the upper and lower lobes of right lung. After the patient received a 
lung cancer chemotherapy, gemcitabine/cisplatin/bevacizumab, the right upper lobe tumor was 
stable in size, and the right lower lobe tumor regressed. Surprisingly, the right lower lobe tumor 
was proven to be metastatic colorectal cancer after surgical resection. A primary rectal tumor 
was then identified through colonoscopy. Subsequently, the patient underwent surgical resec-
tion of the primary rectal cancer and chemotherapy. She has now remained disease-free for 
more than two years. 
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中文摘要 
  結腸直腸癌相關之雙重惡性腫瘤發生率約為百分之一至六，而同時產生結腸直腸癌
及另一原發性惡性腫瘤的發生率更是少於百分之一，其中同時合併原發結腸直腸癌以及
肺癌約為百分之零點一。在這篇文章裡，我們呈現一位罕見病例同時產生原發性肺癌以
及肺部轉移性結腸直腸癌；起初腫瘤位於肺部右上葉及右下葉，在經過 gemcitabine/  
cisplatin/bevacizumab 合併之化學治療後，右上葉腫瘤為穩定狀態而右下葉腫瘤明顯縮
小，術後切片證實右下葉腫瘤為轉移性腺癌，並經結腸鏡檢查證實為直腸癌合併肺轉移。
病患接受原發直腸癌切除術併化學治療後， 超過兩年仍無病存活。 
 
關鍵字: bevacizumab、結腸直腸癌、雙重惡性腫瘤、gemcitabine、肺癌 
 
INTRODUCTION 
Colorectal cancer (CRC) is one of the most com-
mon cancers worldwide [1]. After treating CRC with 
curative resection, the liver is the most common site 
of metastatic recurrence, followed by the lungs [2]. 
Pulmonary metastases of CRC usually present as mul-
tiple tumors; however, approximately 10% consist of a 
solitary pulmonary nodule [3]. For patients who have 
a solitary pulmonary nodule, surgical resection and 
subsequent pathological examination of the tumor 
may be necessary to distinguish metastatic CRC from 
primary lung cancer, because the therapeutic strategies 
for these diseases are different. In rare cases, however, 
patients may developed synchronous CRC and lung 
cancer [4-6]. Here we report a case with concomitant 
primary lung cancer and metastatic pulmonary CRC, 
which responded to gemcitabine/cisplatin/bevacizumab 
combination therapy. 
 
CASE REPORT 
A 48-year-old woman began to suffer from a 
cough with scanty sputum in May 2007. She had nev-
er smoked and had no known family history of cancer. 
The patient visited a local hospital where a computed 
tomography (CT) scan of the chest showed two tu-
mors: one in the right upper lobe (RUL) and the other 
over the right lower lobe (RLL) (Figure 1A,1B). CT 
guided-biopsy of the RLL tumor revealed adenocar-
cinoma. However, immunohistochemical (IHC) stain 
was not done. She was referred to our hospital with a 
suspected diagnosis of primary lung cancer with 
lung-to-lung metastasis. 
In our hospital, another CT scan of the chest re-
vealed one nodular lesion of the RUL 0.5 x 0.5 cm in 
size and the other mass lesion of the RLL 4.4 x 4.2 cm 
in size. The carcinoembryonic antigen (CEA) was 4.3 
ng/ml (normal range: < 5 ng/ml). Treatment was given 
under the diagnosis of primary lung adenocarcinoma 
with lung-to-lung metastasis 【clinical stage: T2N0M1, 
American Joint Committee on Cancer (AJCC), 6th 
edition】, and she received a regimen of gemcitabine/ 
cisplatin/bevacizumab (cemcitabine: 1250 mg/m2 on 
day 1 and day 8; cisplatin: 80 mg/m2 on day 1; and 
bevacizumab: 7.5 mg/kgw on day 1; GCB-G regimen) 
every three weeks for four courses. 
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Figure 1. CT scan of chest before (A,B) and after (C,D) chemotherapy. Arrows indicate the tumor. Significant 
regression was seen in RLL tumor after chemotherapy. RUL: right upper lobe, RLL: right lower lobe 
 
 
Subsequently, a CT scan showed no change in the 
RUL tumor and regression of the RLL tumor (Figure 
1C,1D). The size of the RLL tumor decreased to 2,1 x 
1 cm. Thereafter, she received video-assisted thoraco-
scopic surgery (VATS) for wedge resection of the 
RUL nodule and RLL lobectomy with lymph node 
dissection. No tumor cells could be found in the 
lymph node samples. IHC stains of the RUL nodule 
were positive for cytokeratin 7 (CK7) and thyroid 
transcription factor-1 (TTF-1), and negative for cy-
tokeratin 20 (CK20) and caudal type homeobox 2 
(CDX2) (Figure 2, right lane). These findings were 
consistent with a primary adenocarcinoma. In contrast, 
IHC stains of the RLL tumor revealed an opposite 
pattern (Figure 2, left lane), suggesting metastatic 
CRC [7-9]. Consequently, the patient underwent a 
colonoscopy, which revealed an annular tumor of the 
rectum, 10 cm from the anal verge. Examination of 
the biopsy specimen indicated rectal adenocarcinoma. 
The patient then underwent a laparoscopic low 
anterior resection in December 2007. The final patho-
logical staging of the rectal cancer was pT3N1M1. 
AJCC 6th edition. KRAS sequencing revealed a muta-
tion in codon 12. Because fluorouracil (5-FU) based 
regimen was still a main therapy in metastatic CRC, 
she received combination chemotherapy consisting of 
FOLFOX (fluorouracil (5-FU), leucovorin (LV), and 
oxaliplatin). FOLFOX was administered for 11 cours-
es between January and July 2008. 
Subsequently, the disease recurred on two separate 
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Figure 2. H&E and IHC staining of right lower lobe (left lane) and upper lobe (right lane)  
tumors. Complete opposite patterns were noted. RUL: right upper lobe, RLL: right 
lower lobe. H&E : Hematoxylin and eosin stain; CK7: cytokeratin 7; TTF-1:   
thyroid transcription factor-1; CK20: cytokeratin 20; CDX2: caudal type homeobox 2 
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occasions. The first recurrence became evident in Oc-
tober 2010, when a newly developed nodular lesion 
was found in the RUL of the lung. The patient re-
ceived VATS with wedge resection of the RUL tumor 
in December 2010. Pathological examination indicat-
ed metastatic CRC. She then received 12 cycles of 
chemotherapy, consisting of an LV, 5-FU, and iri-
notecan (FOLFIRI) regimen, which was followed by 
capecitabine maintenance therapy. The second relapse 
occurred in April 2013, when CT scanning revealed 
another tumor in the RUL. VATS with wedge resec-
tion of the RUL tumor was performed in May 2013. 
Pathological examination also indicated metastatic 
CRC. Currently the patient is receiving bevacizumab 
plus mFOLFOX6 therapy. 
 
DISCUSSION 
Double primary malignancy (DPM) is not unusual 
in cases that involve CRC. Yu et al. analyzed more 
than 2000 cases of CRC in which the patients under-
went curative resection. Of these patients, 145 (6.4%) 
developed DPM during follow-up [5]. On the other 
hand, two large case series from Taiwan (each of 
which included more than 1000 cases) found DPM in 
less than 2% of cases involving primary CRC [6,10]. 
Synchronous DPM and CRC is even rarer, with an 
estimated incidence of less than 1% [5,6]. For CRC, 
the common sites of the other primary malignancy 
include the stomach, lung, urinary system, and liver 
[5,6]. The incidence of concurrent CRC and lung can-
cer, in particular, is only 0.1% [5]. Therefore, this 
combination may easily be overlooked because of its 
rarity. 
How to detect the hiding secondary malignancy in 
time is therefore an important issue. Quint et al sug-
gested some methods to distinguish a primary lung 
cancer from metastasis from other sites [11]. One of 
the methods is radiological morphology. With a 
smooth margin, the nodular lesion is more likely to be 
benign or metastatic. In contrast, the diagnosis may be 
a primary lung cancer if the nodule has an irregular or 
blurred margin. As to our patient, the lesion of the 
RUL showed an irregular margin, and the one of the 
RLL a regular margin on the CT. Therefore, the radi-
ological finding of our patient appeared to be compat-
ible with the conclusion of Quint et al. 
It is quite challenging to treat patients who have 
concurrent double primary malignancies. Surgical 
excision is always an option, if both diseases are con-
firmed to small areas. For CRC with pulmonary me-
tastases, several studies have also shown that surgical 
resection of the lung metastatic tumors can greatly 
improve patients’ long-term survival to 20-30% 
[12-14]. However, chemotherapy should be consid-
ered for advanced disease and patients who are not 
suitable enough for surgery. Kaneki et al. reported a 
case with concurrent non-small cell lung cancer 
(NSCLC) and CRC, which was successfully treated 
using irinotecan in combination with cisplatin [15]. 
However, we treated our patient with a GCB-G pro-
tocol, because we thought that her cancer was a lung 
adenocarcinoma only. The gemcitabine-cisplatin (GC) 
doublet has been demonstrated to be efficacious for 
locally advanced NSCLC [16], and the combination of 
GC with bevacizumab has also been shown to im-
prove progression-free survival for patients with met-
astatic NSCLC [17]. Therefore, this combination was 
a reasonable made of treatment for our patient. Sur-
prisingly, the metastatic CRC tumor showed a good 
response to this regimen. In combination with chemo-
therapy, bevacizumab has been used to treat advanced 
CRC with considerable efficacy [18]. However, a few 
studies have suggested that the GC doublet is an ef-
fective regimen for CRC. In a pre-clinical study, the 
combination of gemcitabine with oxaliplatin or cispla-
tin was effective in suppressing the growth of colon 
cancer cell lines although the cytotoxic effects of GC 
were worse than gemcitabine-oxaliplatin combination 
[19]. Additionally, in a phase II trial, 19 patients who 
failed first-line 5-FU-based regimens received 5-FU 
plus LV followed by GC as a second-line treatment. 
Although a partial response was achieved in only one 
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patient (5%), stable disease status was maintained in 
eight (42%) [20]. In this study, the GC doublet had 
only modest activity for pre-treated advanced CRC. 
Therefore, in our case, the efficacy of GCB-G regimen 
may have greatly contributed to gemcitabine and the 
combination with bevacizumab.  
In summary, we have reported an unusual case of 
concurrent primary lung cancer and pulmonary meta-
static CRC. Moreover, the metastatic CRC tumor 
showed an unexpectedly good response to a GCB-G 
regimen, suggesting that this lung cancer chemother-
apy regimen may have potential for treating CRC. 
However, because of its modest effects and lack of 
large randomized controlled trials, we still recommend 
this regimen as a salvage therapy after the failure of 
5-Fluorouracil, oxaliplatin or irinotecan-based chem-
otherapy. Our patient has now remained disease-free 
for over two years after surgical resection of both the 
metastatic and primary rectal tumors, followed by 
chemotherapy. Biopsy and detailed immunohisto-
chemical staining are necessary for correctly diagnos-
ing lung tumors. 
 
REFERENCES 
1. Siegel R, Naishadham D, Jemal A. Cancer statis-
tics, 2012. CA Cancer J Clin 62: 10-29, 2012. 
2. Tsikitis VL, Malireddy K, Green EA, et al. Post-
operative surveillance recommendations for early 
stage colon cancer based on results from the clin-
ical outcomes of surgical therapy trial. J Clin 
Oncol 27: 3671-3676, 2009. 
3. Lee WS, Yun SH, Chun HK, et al. Pulmonary 
resection for metastases from colorectal cancer: 
prognostic factors and survival. Int J Colorectal 
Dis 22: 699-704, 2007. 
4. Peng YF, Gu J. Synchronous colorectal and lung 
cancer: report of three cases. World J Gastroen-
terol 14: 969-973, 2008. 
5. Yun HR, Yi LJ, Cho YK, et al. Double primary 
malignancy in colorectal cancer patients--MSI is 
the useful marker for predicting double primary 
tumors. Int J Colorectal Dis 24: 369-375, 2009. 
6. Chiang JM, Yeh CY, Changehien CR, et al. Clini-
cal features of second other-site primary cancers 
among sporadic colorectal cancer patients--a hos-
pital-based study of 3,722 cases. Hepatogastro-
enterology 51: 1341-1344, 2004. 
7. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 ex-
pression in pulmonary adenocarcinomas. Am J 
Surg Pathol 26: 767-773, 2002. 
8. Kummar S, Fogarasi M, Canova A, et al. Cy-
tokeratin 7 and 20 staining for the diagnosis of 
lung and colorectal adenocarcinoma. Br J Cancer 
86: 1884-1887, 2002. 
9. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a 
highly sensitive and specific marker of adenocar-
cinomas of intestinal origin: an immunohisto-
chemical survey of 476 primary and metastatic 
carcinomas. Am J Surg Pathol 27: 303-310, 
2003. 
10. Kan JY, Hsieh JS, Pan YS, et al. Clinical charac-
teristics of patients with sporadic colorectal  
cancer and primary cancers of other organs. 
Kaohsiung J Med Sci 22: 547-553, 2006. 
11. Quint LE, Park CH, Iannettoni MD. Solitary pul-
monary nodules in patients with extrapulmonary 
neoplasms. Radiology 217: 257-261, 2000. 
12. Yedibela S, Klein P, Feuchter K, et al. Surgical 
management of pulmonary metastases from colo-
rectal cancer in 153 patients. Ann Surg Oncol 13: 
1538-1544, 2006. 
13. Saito Y, Omiya H, Kohno K, et al. Pulmonary 
metastasectomy for 165 patients with colorectal 
carcinoma: A prognostic assessment. J Thorac 
Cardiovasc Surg 124: 1007-1013, 2002. 
14. Girard P, Ducreux M, Baldeyrou P, et al. Surgery 
for lung metastases from colorectal cancer: analy-
sis of prognostic factors. J Clin Oncol 14: 2047- 
2053, 1996. 
15. Kaneki T, Koizumi T, Kawashima A, et al. Double 
cancer (lung and colon cancer) that showed com-
plete remission with irinotecan and cisplatin com-
H. M. Chen et al./JCRP 2(2015) 76-82 81
bined chemotherapy. J Gastroenterol 35: 864- 
869, 2000. 
16. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. 
Randomized phase III study of surgery alone or 
surgery plus preoperative cisplatin and gemcita-
bine in stages IB to IIIA non-small-cell lung can-
cer. J Clin Oncol 30: 172-178, 2012. 
17. Reck M, von PJ, Zatloukal P, et al. Phase III trial 
of cisplatin plus gemcitabine with either placebo 
or bevacizumab as first-line therapy for nonsqua-
mous non-small-cell lung cancer: AVAil. J Clin 
Oncol 27: 1227-1234, 2009. 
18. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. 
Bevacizumab in combination with fluorouracil 
and leucovorin: an active regimen for first-line 
metastatic colorectal cancer. J Clin Oncol 23: 
3502-3508, 2005. 
19. Faivre S, Raymond E, Woynarowski JM, et al. Su-
praadditive effect of 2', 2'-difluorodeoxycytidine 
(gemcitabine) in combination with oxaliplatin in 
human cancer cell lines. Cancer Chemother 
Pharmacol 44: 117-123, 1999. 
20. Chang AY, Lopes G, Hsin KW, et al. Phase II trial 
of 5-fluorouracil/leucovorin/ gemcitabine/cisplatin 
as second-line treatment in patients with meta-
static or recurrent colorectal carcinoma: a cancer 
therapeutics research group study. Clin Colorec-
tal Cancer 6: 646-651, 2007. 
 
82 H. M. Chen et al./JCRP 2(2015) 76-82
